Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Cardiovascular
Immunology
Ophthalmology
ganaplacide - Non-artemisinin plasmodium
falciparum inhibitor
NCT04546633 KALUMI (CKAF156A2203)
Conclusions
Indication
Malaria, uncomplicated
Phase
Phase 2
Patients
292
Primary
Outcome
Measures
Arms
Intervention
PCR-corrected and uncorrected Adequate Clinical and Parasitological
Response (ACPR)
KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
Target
Patients
Malaria patients 6 months to < 18 years old
Readout
Milestone(s)
Publication
2023
TBD
Neuroscience
Global Health
Appendix
Innovation: Clinical trials
References
Abbreviations
Oncology
Other
Biosimilars
90 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation